Deamidation is influenced by pH, temperature, and the surrounding amino acid sequence
Injection-site issues: redness, swelling, or irritation are common to any SubQ injection and are made worse by poor technique or low-quality product
If additional glycaemic control is required after at least 30 days on the 7 mg dose, it may be increased to the maximum dose of 14 mg once daily
Additionally, there are limitations in current clinical trial endpoints, like categorical fibrosis staging in assessing treatment effectiveness
Nausea, vomiting, constipation, and appetite suppression occur with semaglutide, tirzepatide, and retatrutide, though timing and severity vary